Glossary · Biology
LDL and ApoB
In short
LDL cholesterol measures how much cholesterol is transported through the blood in LDL particles; ApoB counts the particles themselves. Both are considered causes of atherosclerosis, not just companions.
Every artery-damaging transport particle carries exactly one ApoB molecule. Usually LDL cholesterol and ApoB run in parallel. With high triglycerides, obesity or diabetes, however, many small particles with little cholesterol can be circulating — then ApoB reflects the risk more precisely.
That LDL is causal rests on three independent lines of evidence: large cohorts, Mendelian randomization and randomized trials with different lowering drugs. The lower and longer the reduction, the fewer heart attacks — a rare example of a marker that is well supported as a surrogate.
More on the test is on the topic page ApoB test. Lipoprotein(a) is a separate risk factor that is largely inherited.
LDL measures the load, ApoB counts the carriers.
Where this comes up in the fact checks
- Statins – Lower LDL and heart attacks, as 26 large trials show.
- Ezetimibe – Slows cholesterol absorption in the gut and lowers LDL; the added benefit remains small.
- Bempedoic acid – Lowers LDL without a statin and, in CLEAR Outcomes, major cardiovascular events from 13.3 to 11.7 percent.
Sources
Related terms: Mendelian randomization · Surrogate marker · Biomarker
Information only, not medical advice. The BK-Score is a subjective assessment according to disclosed rules – not a scientific evaluation. Scoring rules